Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Gene Ther. 2009 Jul 30;16(11):1300–1313. doi: 10.1038/gt.2009.93

Figure 7. Immunization with genetically modified B cells protects against tumor growth in a therapeutic setting.

Figure 7

(A) Mice were inoculated subcutaneously with 106 EG-7 tumor cells and either not immunized (Control), or immunized at days 3 and 6 post tumor inoculation (p.t.i.) with 105 OVA-transgenic unstimulated or stimulated B cells or bone marrow-derived DCs. Arrows represent times of immunization. Tumor volumes ± SE are presented as averages of 4 to 5 mice per group. (B) Tumor growth curves in individual mice. (C) Correlation between the frequency of OVA-1-specific CD8+ T cells in blood of mice at day 10 post tumor inoculation determined by specific pentamer staining and tumor volume at day 12. R, correlation coefficient. (D) As in (A) except that mice were immunized with OVA peptide-pulsed B cells.